Actively Recruiting
Evaluation of the Prognostic Value of PET/MRI in Cardiac Sarcoidosis
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-04-02
180
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Cardiac damage is the second leading cause of death in patients with sarcoidosis, after lung damage. Today's challenge is to diagnose the disease as effectively as possible, and to develop tools for better risk stratification, especially for sudden death, in order to better target therapies and implantable devices, such as corticoids and immunosuppressant. The hypothesis is that combined PET (Positron Emission Tomography)/MRI (Magnetic Resonance Imaging) could be a relevant prognostic marker of progression, and would significantly improve diagnostic performance in patients with suspected cardiac sarcoidosis (CS). This study will also make it possible to distinguish sequellar fibrosis lesions from granulomatous lesions and assess the therapeutic response. Incorporating PET/MRI into the diagnostic strategy for patients with suspected CS could therefore improve their management.
CONDITIONS
Official Title
Evaluation of the Prognostic Value of PET/MRI in Cardiac Sarcoidosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosis of sarcoidosis according to ATS/ERS/WASOG criteria
- Suspicion of cardiac involvement based on clinical symptoms (such as syncope, palpitations, heart failure signs), or cardiac rhythm or conduction disorders, or compatible cardiac ultrasound abnormalities
- Provided informed consent
- Member of a social security scheme
You will not qualify if you...
- Uncontrolled psychiatric illness
- Claustrophobia
- Known pregnancy or breastfeeding
- Unbalanced diabetes affecting carbohydrate metabolism
- Previous heart attack or known coronary disease
- Allergy to gadolinium, fluoro-desoxyglucose, or their components
- Severe kidney failure (creatinine clearance < 30 mL/min/1.73m2)
- Implanted pacemaker incompatible with a 3 Tesla MRI
- Presence of ocular metallic foreign bodies or certain implanted electronic devices (neurostimulators, cochlear implants, metallic heart valves, vascular clips)
- Unable or unwilling to follow a low-carbohydrate diet for 24 hours plus 6-hour fast before scan
- Unable to hold breath for 10 seconds during examination
- Legal restrictions such as deprivation of liberty or legal protection
- Participation in other interventional studies or within exclusion period
- Patients under AME
- Positive pregnancy test after inclusion for women of reproductive age
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Henri Mondor Hospital
Créteil, France
Actively Recruiting
Research Team
V
Vania TACHER, PHD
CONTACT
S
Samia BALOUL
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here